L 698532
Latest Information Update: 06 Oct 1998
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Class Antiepileptic drugs
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Seizures
Most Recent Events
- 06 Oct 1998 No-Development-Reported for Seizures in United Kingdom (Unknown route)
- 01 May 1996 Preclinical development for Seizures in United Kingdom (Unknown route)